Form 4: Revolution Medicines CEO Acquires Shares and Options in Recent Transaction
SEC Filing
Mark A. Goldsmith, CEO of Revolution Medicines, reports acquisition of shares and options, including restricted stock units and stock options, as per a recent SEC filing.
Summary
- Mark A. Goldsmith, the CEO of Revolution Medicines, filed a Form 4 with the SEC.
- The filing details changes in his beneficial ownership of the company's securities.
- On March 1, 2025, Goldsmith acquired 97,400 shares of common stock.
- He also acquired 341,100 stock options with an exercise price of $40.74.
- These options vest monthly from March 1, 2025, over four years.
- Goldsmith directly owns 453,302 shares and indirectly owns shares through several trusts.
- These trusts include the Jonathan Goldsmith Revocable Trust, the Rebecca Eve Goldsmith Trust, and the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard SEC filing reflecting insider transactions. The CEO's acquisition could be seen as a positive signal, but it's not definitively bullish.
Positives
- The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The stock options vest monthly from March 1, 2025, over four years, contingent on the Reporting Person's continued service.
Industry Context
This filing is a routine disclosure required by the SEC when company insiders trade in their own company's stock. It provides transparency to investors about the actions of key personnel.
Stakeholder Impact
- Shareholders may view the CEO's stock acquisition as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2011-12-15 | Date of the Goldsmith Children's 2011 Irrevocable Education Trust |
| 2025-03-01 | Date of the transaction and Vesting Commencement Date for stock options |
| 2025-03-04 | Date of the signature on the SEC filing |
| 2035-02-28 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.